The global factor VIII deficiency treatment market is currently valued at around USD 9 billion and is expected to surpass USD 11 billion by 2021, says Technavio.
Technavio has announced its latest market research report on the global factor VIII deficiency treatment market, under its rare and infectious diseases portfolio. This market analysis discusses the major drivers and key emerging trends and offers an analysis of key vendors like Bayer HealthCare, CSL, Grifols, Novo Nordisk, Pfizer, and Shire.
According to Barath Palada, a lead analyst for rare and infectious diseases research at Technavio, “Vendors in the global factor VIII are focusing on the development of prophylactic drugs. In September 2015, F. Hoffmann La-Roche received breakthrough therapy designation for ACE910, a prophylactic treatment for individuals of ages 12 and above.”
The prophylactic treatment approach helps in preventing spontaneous bleeding episodes, increases the quality of life in terms of physical activities, and retains the level of clotting factors above a baseline. Furthermore, the use of prophylactic drugs could reduce the economic burden on factor VIII treatment.
Click here to request a free sample of this report
Increase in technological innovations
At present, most of the hemophilia therapeutics available in the market are short-acting and exhibit and exhibit immunogenic reactions. Technologies such as recombinant DNA, protein fusion technology, and PEGylation technologies were developed and applied in the production of new therapies with a longer lifespan and fewer immunogenic reactions in order to mitigate such issues. For instance, Biogen is developing rFVIIIFc, a recombinant next-generation therapeutic product for hemophilia A therapy.
Development of gene therapy products
Gene therapy is expected to help people with hemophilia A individuals by allowing them to produce their own clotting factor, lessening the need for or reducing the number of weekly infusions. Several gene therapies for factor VIII deficiency are in developmental stages. For instance, in April 2016, BioMarin Pharmaceutical reported positive data in its phase I/II study evaluating BMN 270 (a potential gene therapy candidate).
Ask an analyst to know more about this report
This research report includes an in-depth analysis and market shares and sizes of the sub-segments and geography. An analysis of the key companies, including their market shares, business overview, key financials, etc. is provided in this study. This market study also provides a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio report titled, ‘Global Factor VIII Deficiency Treatment Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Hemophilia Drugs Market 2016-2020
- Global Blood Coagulation Analyzer Market 2016-2020
- Global Alpha-1 Antitrypsin Drugs Market 2016-2020
To read more press releases – click here
